Novartis AG (NVS)
NYSE: NVS · IEX Real-Time Price · USD
97.44
-1.62 (-1.64%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Novartis AG Revenue
Novartis AG had revenue of $49.92B in the twelve months ending March 31, 2024, with 8.81% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $12.12B with 9.71% year-over-year growth. In the year 2023, Novartis AG had annual revenue of $46.66B with 7.36% growth.
Revenue (ttm)
$49.92B
Revenue Growth
+8.81%
P/S Ratio
3.82
Revenue / Employee
$656,402
Employees
76,057
Market Cap
190.64B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
Dec 31, 2018 | 46.10B | 2.70B | 6.21% |
Dec 31, 2017 | 43.40B | -6.03B | -12.20% |
Dec 31, 2016 | 49.44B | -951.00M | -1.89% |
Dec 31, 2015 | 50.39B | -3.25B | -6.05% |
Dec 31, 2014 | 53.63B | 918.00M | 1.74% |
Dec 31, 2013 | 52.72B | 745.00M | 1.43% |
Dec 31, 2012 | 51.97B | -7.40B | -12.47% |
Dec 31, 2011 | 59.38B | 7.81B | 15.15% |
Dec 31, 2010 | 51.56B | 6.46B | 14.32% |
Dec 31, 2009 | 45.10B | 2.52B | 5.92% |
Dec 31, 2008 | 42.58B | 3.64B | 9.34% |
Dec 31, 2007 | 38.95B | 3.84B | 10.94% |
Dec 31, 2006 | 35.11B | 5.35B | 17.99% |
Dec 31, 2005 | 29.75B | 2.48B | 9.08% |
Dec 31, 2004 | 27.28B | 2.35B | 9.41% |
Dec 31, 2003 | 24.93B | 4.05B | 19.41% |
Dec 31, 2002 | 20.88B | 2.12B | 11.27% |
Dec 31, 2001 | 18.76B | -3.07B | -14.06% |
Dec 31, 2000 | 21.83B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
Pfizer | 58.50B |
AbbVie | 54.32B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
Amgen | 28.19B |
NVS News
- 4 days ago - Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies - GlobeNewsWire
- 4 days ago - Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors - GlobeNewsWire
- 4 days ago - Novartis Exceeds Q1 Forecasts, Boosts Outlook as Blockbuster Drug Sales Climb - Investopedia
- 5 days ago - Novartis shares jump as drugmaker boosts outlook - Market Watch
- 5 days ago - Shares of Novartis climb 4.8% on raised guidance, better-than-expected results - CNBC
- 5 days ago - Novartis Ups Guidance on Profit, Sales Growth - WSJ
- 5 days ago - Novartis lifts FY guidance after Q1 results beat expectations - Reuters
- 5 days ago - Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised - GlobeNewsWire